Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
Lambert G, Petrides F, Chatelais M, Blom DJ, Choque B, Tabet F, Wong G, Rye KA, Hooper AJ, Burnett JR, Barter PJ, Marais AD. Lambert G, et al. Among authors: petrides f. J Am Coll Cardiol. 2014 Jun 10;63(22):2365-73. doi: 10.1016/j.jacc.2014.02.538. Epub 2014 Mar 12. J Am Coll Cardiol. 2014. PMID: 24632287 Free article.
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
Arsenault BJ, Petrides F, Tabet F, Bao W, Hovingh GK, Boekholdt SM, Ramin-Mangata S, Meilhac O, DeMicco D, Rye KA, Waters DD, Kastelein JJP, Barter P, Lambert G. Arsenault BJ, et al. Among authors: petrides f. J Clin Lipidol. 2018 Jan-Feb;12(1):130-136. doi: 10.1016/j.jacl.2017.10.001. Epub 2017 Oct 12. J Clin Lipidol. 2018. PMID: 29103916 Clinical Trial.
Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.
Lambert G, Chatelais M, Petrides F, Passard M, Thedrez A, Rye KA, Schwahn U, Gusarova V, Blom DJ, Sasiela W, Marais AD. Lambert G, et al. Among authors: petrides f. J Am Coll Cardiol. 2014 Dec 2;64(21):2299-300. doi: 10.1016/j.jacc.2014.07.995. Epub 2014 Nov 24. J Am Coll Cardiol. 2014. PMID: 25456764 Free article. No abstract available.
Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment.
Kwakernaak AJ, Lambert G, Slagman MC, Waanders F, Laverman GD, Petrides F, Dikkeschei BD, Navis G, Dullaart RP. Kwakernaak AJ, et al. Among authors: petrides f. Atherosclerosis. 2013 Feb;226(2):459-65. doi: 10.1016/j.atherosclerosis.2012.11.009. Epub 2012 Nov 29. Atherosclerosis. 2013. PMID: 23261172 Clinical Trial.
The promises of PCSK9 inhibition.
Petrides F, Shearston K, Chatelais M, Guilbaud F, Meilhac O, Lambert G. Petrides F, et al. Curr Opin Lipidol. 2013 Aug;24(4):307-12. doi: 10.1097/MOL.0b013e328361f62d. Curr Opin Lipidol. 2013. PMID: 23817198 Review.
Beyond LDL cholesterol, a new role for PCSK9.
Akram ON, Bernier A, Petrides F, Wong G, Lambert G. Akram ON, et al. Among authors: petrides f. Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1279-81. doi: 10.1161/ATVBAHA.110.209007. Arterioscler Thromb Vasc Biol. 2010. PMID: 20554949 No abstract available.
Proprotein convertase subtilisin/kexin type 9 inhibition.
Marais DA, Blom DJ, Petrides F, Gouëffic Y, Lambert G. Marais DA, et al. Among authors: petrides f. Curr Opin Lipidol. 2012 Dec;23(6):511-7. doi: 10.1097/MOL.0b013e3283587563. Curr Opin Lipidol. 2012. PMID: 22907332 Review.
18 results